Download PDF
Thromb Haemost 2010; 104(03): 571-581
DOI: 10.1160/TH09-11-0803
Platelets and Blood Cells
Schattauer GmbH

Differential sensitivity and kinetics of response of different ex vivo tests monitoring functional variability of platelet response to clopidogrel

Claire Bal dit Sollier
1   IVS, Hôpital Lariboisière, Paris, France
,
Natacha Berge
1   IVS, Hôpital Lariboisière, Paris, France
,
Bernadette Boval
2   Haematology Laboratory, Hôpital Lariboisière, Paris, France
,
Michel Dubar
3   Sanofi-Aventis Recherche, Chilly-Mazarin, France
,
Ludovic Drouet
2   Haematology Laboratory, Hôpital Lariboisière, Paris, France
› Author Affiliations Financial support: This study was supported by a research grant from sanofi-aventis and Bristol-Myers Squibb.
Further Information

Publication History

Received: 30 November 2009

Accepted after major revision: 04 May 2010

Publication Date:
23 November 2017 (online)

Also available at
    Permissions and Reprints

Summary

We previously showed that variability of response to clopidogrel is linked to occupancy of the P2Y12 receptor by clopidogrel active-metabolite, and that maximal platelet aggregation intensity (MAI) measured by light transmission aggregometry (LTA) correlates with occupancy. The present study compared a range of ex vivo platelet tests at various levels of P2Y12 occupancy. After screening with clopidogrel 75 mg/day for seven days, subjects were selected to obtain ‘low’, ‘average’ and ‘high’ responders and randomised to clopidogrel (75 mg/day days 1–10; 300 mg day 11), or placebo. Assays were LTA in platelet-rich plasma using 2, 5 and 20 μM ADP, VerifyNow® P2Y12, flow cytometric analysis of platelet activation markers and vasodilator-stimulated phospho-protein (VASP) index, and a thromboelastographic test that is sensitive to clopidogrel. The reference test was P2Y12 receptor occupancy, measured by binding of 33P-2MeS-ADP to platelets. MAI showed the best correlation with P2Y12 occupancy. Similar results were seen with different ADP concentrations and when LTA data were expressed as inhibition of platelet aggregation. A plot of free receptors/cell versus VASP index was biphasic, with poor correlation for low-level P2Y12 occupancy. Sensitivity of the VerifyNow P2Y12 assay decreased at higher clopidogrel responses. Thromboelastography and P-selectin expression had poor correlation with receptor occupancy. In conclusion, LTA data correlate best with P2Y12 occupancy, the gold standard for detecting clopidogrel’s effect at the receptor level. Our results highlight a limitation of the VASP index, which appears unable to distinguish low, average and high responders early after clopidogrel initiation when P2Y12 occupancy is still low.

Keywords

Clopidogrel - flow cytometry - platelet
 

  • References

  • 1 Bassand J-P. et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. The Task Force for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes for the European Society of Cardiology. Eur Heart J 2007; 28: 1598-1660.
    CrossrefPubMedSearch in Google Scholar
  • 2 Van de Werf F. et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. Eur Heart J 2008; 29: 2909-2945.
    CrossrefPubMedSearch in Google Scholar
  • 3 Anderson JL. et al. ACC/AHA guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction). Circulation 2007; 116: 803-877.
    CrossrefPubMedSearch in Google Scholar
  • 4 Antman EM. et al. 2007 focused update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Group to Review New Evidence and Update the 2002 ACC/AHA 2004 guidelines for the Management of Patients with ST-Elevation Myocardial Infarction). Circulation 2008; 117: 296-329.
    CrossrefPubMedSearch in Google Scholar
  • 5 King SB III. et al. 2007 focused update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: (2007 Working Group to Review New Evidence and Update the 2005 ACC/AHA/SCAI Guideline Update for Percutaneous Coronary Intervention). J Am Coll Cardiol 2008; 51: 172-209.
    CrossrefPubMedSearch in Google Scholar
  • 6 Hirsch AT. et al. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease). Circulation 2006; 113: e463-e654.
    CrossrefPubMedSearch in Google Scholar
  • 7 Sacco RL. et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke, cosponsored by the Council on Cardiovascular Radiology and Intervention. Stroke 2006; 37: 577-617.
    CrossrefPubMedSearch in Google Scholar
  • 8 Gurbel PA. et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107: 2908-2913.
    CrossrefPubMedSearch in Google Scholar
  • 9 Gurbel P, Tantry U. Drug insight: clopidogrel nonresponsiveness. Nat Clin Pract Cardiovasc Med 2006; 3: 387-395.
    CrossrefPubMedSearch in Google Scholar
  • 10 Siller-Matula J. et al. Thienopyridines in cardiovascular disease: focus on clopidogrel resistance. Thromb Haemost 2007; 97: 385-393.
    Thieme ConnectPubMedSearch in Google Scholar
  • 11 Neubauer H. et al. How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification. Thromb Haemost 2008; 99: 357-362.
    Thieme ConnectPubMedSearch in Google Scholar
  • 12 De Miguel A. et al. Clinical implications of clopidogrel resistance. Thromb Haemost 2008; 100: 196-203.
    Thieme ConnectPubMedSearch in Google Scholar
  • 13 Serebruany V. et al. Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease. Thromb Haemost 2008; 100: 76-82.
    Thieme ConnectPubMedSearch in Google Scholar
  • 14 Béres BJ. et al. Analysis of platelet α2-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy. Thromb Haemost 2008; 100: 829-838.
    Thieme ConnectPubMedSearch in Google Scholar
  • 15 Gremmel T. et al. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation. Thromb Haemost 2009; 101: 333-339.
    Thieme ConnectPubMedSearch in Google Scholar
  • 16 Sibbing D. et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 2009; 101: 714-719.
    Thieme ConnectPubMedSearch in Google Scholar
  • 17 Ferreiro JL, Angiolillo DJ. Clopidogrel response variability: Current status and future directions. Thromb Haemost 2009; 102: 7-14.
    Thieme ConnectPubMedSearch in Google Scholar
  • 18 Elsenberg EHAM. et al. The influence of clinical characteristics, laboratory and inflammatory markers on ‘high on-treatment platelet reactivity’ as measured with different platelet function tests. Thromb Haemost 2009; 102: 719-727.
    Thieme ConnectPubMedSearch in Google Scholar
  • 19 Zürn CS. et al. ADP-receptor blockade: A case for personalised pharmacotherapy?. Thromb Haemost 2010; 103: 496-506.
    Thieme ConnectPubMedSearch in Google Scholar
  • 20 Williams CD. et al. Application of platelet function testing to the bedside. Thromb Haemost 2010; 103: 29-33.
    Thieme ConnectPubMedSearch in Google Scholar
  • 21 Sibbing D. et al. Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting. Thromb Haemost 2010; 103: 151-159.
    Thieme ConnectPubMedSearch in Google Scholar
  • 22 Montalescot G. et al. Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study. Thromb Haemost 2010; 103: 213-223.
    Thieme ConnectPubMedSearch in Google Scholar
  • 23 Sofi F. et al. Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis. Thromb Haemost 2010; 103: 841-848.
    Thieme ConnectPubMedSearch in Google Scholar
  • 24 Malinin A. et al. Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel. Methods Find Exp Clin Pharmacol 2006; 28: 315-322.
    CrossrefPubMedSearch in Google Scholar
  • 25 Craft RM. et al. A novel modification of the Thromboelastograph assay, isolating platelet function, correlates with optical platelet aggregation. J Lab Clin Med 2004; 143: 301-309.
    CrossrefPubMedSearch in Google Scholar
  • 26 Schwarz UR. et al. Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets – definition and detection of ticlopidine/clopidogrel effects. Thromb Haemost 1999; 82: 1145-1152.
    Thieme ConnectPubMedSearch in Google Scholar
  • 27 Gurbel PA. et al. Platelet reactivity in patients and recurrent events post-stenting. Results of the PREPARE POST-STENTING study. J Am Coll Cardiol 2005; 46: 1820-1826.
    CrossrefPubMedSearch in Google Scholar
  • 28 Hochholzer W. et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006; 48: 1742-1750.
    CrossrefPubMedSearch in Google Scholar
  • 29 Pampuch A. et al. Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor. Thromb Haemost 2006; 96: 767-773.
    Thieme ConnectPubMedSearch in Google Scholar
  • 30 Jakubowski JA. et al. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry. Thromb Haemost 2007; 99: 215-222.
    Thieme ConnectPubMedSearch in Google Scholar
  • 31 Paniccia R. et al. Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. J Thromb Haemost 2007; 5: 1839-1847.
    CrossrefPubMedSearch in Google Scholar
  • 32 Van Werkum JW. et al. A comparison between the Plateletworks™ assay and light transmittance aggregometry for monitoring the inhibitory effects of clopidogrel. Int J Cardiol 2010; 140: 123-126.
    CrossrefPubMedSearch in Google Scholar
  • 33 Bal dit Sollier C. et al. Functional variability of platelet response to clopidogrel correlates with P2Y12 receptor occupancy. Thromb Haemost 2009; 101: 116-122.
    Thieme ConnectPubMedSearch in Google Scholar
  • 34 Born GV, Cross MJ. The aggregation of blood platelets. J Physiol 1963; 168: 178-195.
    CrossrefPubMedSearch in Google Scholar
  • 35 Savi P. et al. P2Y12, a new platelet ADP receptor, target of clopidogrel. Biochem Biophys Res Commun 2001; 283: 379-383.
    CrossrefPubMedSearch in Google Scholar
  • 36 Savi P, Herbert JM. Use of radiolabeled 2-methylthio-ADP to study P2Y receptors on platelets and cell lines. Methods Mol Biol 2004; 273: 115-124.
    PubMedSearch in Google Scholar
  • 37 Aleil B. et al. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 2005; 3: 85-92.
    CrossrefPubMedSearch in Google Scholar
  • 38 Schäfer A. et al. ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay. Thromb Haemost 2008; 100: 618-625.
    Thieme ConnectPubMedSearch in Google Scholar
  • 39 Blindt R. et al. The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. Thromb Haemost 2007; 98: 1329-1334.
    Thieme ConnectPubMedSearch in Google Scholar
  • 40 Butt E. et al. cAMP- and cGMP-dependent protein kinase phosphorylation sites of the focal adhesion vasodilator-stimulated phosphorylation (VASP) in vitro and in intact human platelets. J Biol Chem 1994; 269: 14509-14517.
    PubMedSearch in Google Scholar
  • 41 Geiger J. et al. Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signalling by the antiplatelet drug clopidogrel. Arterioscler Thromb Vasc Biol 1999; 19: 2007-2011.
    CrossrefPubMedSearch in Google Scholar
  • 42 Jakubowski JA. et al. The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration. Thromb Haemost 2008; 99: 409-415.
    Thieme ConnectPubMedSearch in Google Scholar
  • 43 Varenhorst C. et al. Assessment of P2Y12 inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin. Am Heart J 2009; 157: 562.e1-562.e9.
    CrossrefPubMedSearch in Google Scholar